JA
Jiangsu Aidea Pharmaceutical at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Jiangsu Aidea Pharmaceutical brings 3 presentations to IDWeek 2026 in Washington. Its program centres on HIV antiretroviral drugs, including early-phase trials of asuptegravir in healthy adults and in people new to treatment. A long-term switch study links an ainuovirine, lamivudine and tenofovir combination to lasting viral suppression and cardiometabolic benefits.
| Organization | IDWeek 2026 Attendance |
|---|---|
JA Jiangsu Aidea Pharmaceutical | |
Chinese drug company developing HIV antiretrovirals, including the integrase inhibitor asuptegravir. | Poster Fri Oct 23 12:15pm–1:30pm Long-Term Viral Suppression and Cardiometabolic Benefits of Switching to Ainuovirine/Lamivudine/Tenofovir DF in Virologically Suppressed People with HIV-1: 192-Week Extended Results from the SPRINT Study Poster Sat Oct 24 12:15pm–1:30pm Pharmacokinetics, Predicted Antiviral Activity, and Safety of Single-Ascending-Dose Asuptegravir, A New-Generation Integrase Strand Transfer Inhibitor, in Healthy Adults: A Two-Period, Randomized, Placebo-Controlled Phase 1 Study Poster Sat Oct 24 12:15pm–1:30pm Viral Kinetics, Pharmacokinetics, And Exposure-Response Analysis of Monotherapy of Multiple Ascending Dose Asuptegravir, a New-Generation Integrase Strand Transfer Inhibitor, Followed by Combination with Emtricitabine And Tenofovir Alafenamide in Treatment-Naïve People Living with HIV-1: a Two-Period, Randomized, Placebo-Controlled Phase 1/2 Study. |
Instantly find 20 buyers from Jiangsu Aidea Pharmaceutical
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction